晚期肾细胞癌的免疫治疗现状与进展  

Current status and advances in immunotherapy for advanced renal cell carcinoma

作　　者：陈茹雁 付振明 Chen Ruyan;Fu Zhenming(Department of Oncology,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,武汉430060

出　　处：《国际肿瘤学杂志》2025年第2期124-128,共5页Journal of International Oncology

摘　　要：约25%的肾细胞癌(RCC)患者在初诊时就已处于晚期,并且有近30%局限性RCC患者在根治性手术后仍发生远处转移。传统的化疗以及放疗方案对晚期RCC患者的治疗效果十分有限,因此晚期RCC患者的预后较差,5年生存率约为8%。近几年RCC的免疫治疗成为了研究热点,随着研究的不断深入,晚期RCC患者的治疗越来越多样化。探讨晚期RCC的免疫治疗的临床应用现状以及相关研究进展,可以为晚期RCC患者治疗方案的选择提供医学证据。Approximately 25%of renal cell carcinoma(RCC)patients are already at an advanced stage at the time of initial diagnosis.Additionally,nearly 30%of patients with localized RCC eventually develop distant metastases even after undergoing radical surgery.Traditional chemotherapy and radiotherapy have shown limited effect on advanced RCC treatment,resulting in poor prognosis,with a 5-year survival rate of only about 8%.In recent years,immunotherapy for RCC has become a significant focus of research.With further research,the treatment options for advanced RCC have become increasingly diverse.The exploration of the current clinical applications and research advancements in immunotherapy for advanced RCC could offer medical evidence for optimizing treatment strategies for advanced RCC patients.

关 键 词：癌 肾细胞 免疫疗法 免疫检查点抑制剂 

分 类 号：R737.11[医药卫生—肿瘤]